Lepu Biopharma Co. Ltd. has announced the results of a pivotal clinical trial for their drug candidate, MRG003, which were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study focused on the treatment of recurrent or metastatic nasopharyngeal cancer (R/M NPC) using MRG003, a novel EGFR-targeted antibody-drug conjugate. In a randomized-controlled, multicenter, open-label study, MRG003 demonstrated statistically and clinically significant benefits in heavily pretreated patients compared to chemotherapy. The trial enrolled 173 patients, with MRG003 showing a higher objective response rate of 30.2% compared to 11.5% for chemotherapy. The study highlights a potential shift in treatment paradigms for R/M NPC. However, the company cautions that there is no guarantee of MRG003's successful development and market launch.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。